# TAXOL® (paclitaxel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/paclitaxel

> The FDA approved TAXOL® (paclitaxel), sponsored by TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), on March 25, 2026 for severe endocrinologic, oncologic, metabolic and neurologic disorders.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TAXOL® (paclitaxel) |
| Codes |  |
| Sponsor | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) https://sec-api.dev/companies/teva/catalysts |
| Indications | with platinum-resistant ovarian cancer, [advanced btc](https://sec-api.dev/indications/advanced-btc), [severe endocrinologic, oncologic, metabolic and neurologic disorders](https://sec-api.dev/indications/severe-endocrinologic-oncologic-metabolic-and-neurologic-disorders), [platinum-resistant ovarian cancer](https://sec-api.dev/indications/platinum-resistant-ovarian-cancer), high-impact, difficult-to-treat cancers |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### May 11, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216338 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230511, review_priority STANDARD; sponsor_name TEVA PHARMS INC; product PACLITAXEL (PACLITAXEL)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216338%22

### November 21, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216338 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20231121, review_priority STANDARD; sponsor_name TEVA PHARMS INC; product PACLITAXEL (PACLITAXEL)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216338%22

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: advanced BTC.
- First seen 2024-11-12, last confirmed 2025-02-27.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001105): "Top-line data readout in the U.S. on track for the end of Q1 2025 for COMPANION-002, the Company's Phase 2/3 randomized trial of tovecimig in combination with paclitaxel in patients with advanced BTC." https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000116): "Top-line data readout in the U.S. on track for the end of Q1 2025 for COMPANION-002, the Company's Phase 2/3 randomized trial of tovecimig in combination with paclitaxel in patients with advanced BTC (see press release)." https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/exh_991.htm
- SEC Form 10-K (accession 0001171843-25-001106): "We expect top-line data from this study at the end of the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1738021/000117184325001106/cmpx20241231_10k.htm
- SEC Form 10-Q (accession 0001171843-24-006248): "This trial was fully enrolled in August 2024 and top line data from this study is expected at the end of the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1738021/000117184324006248/cmpx20240930_10q.htm

### May 6, 2025: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 2. Indication: high-impact, difficult-to-treat cancers.
- First seen 2025-05-06, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001683168-25-003163): "CHICAGO, IL and FORT WORTH, TX, May 6, 2025 - Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results from its ongoing Phase 2 (Actuate-1801 Part" https://www.sec.gov/Archives/edgar/data/1652935/000168316825003163/actuate_ex9901.htm

### March 25, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: severe endocrinologic, oncologic, metabolic and neurologic disorders.
- First seen 2026-03-25, last confirmed 2026-03-25.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-123543): "Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475dex991.htm

### Apr 2026: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2026-11-03, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001193125-26-444376): "Additionally, in April 2026 the first patient was dosed in our Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), from which we expect to report interim data in 2027." https://www.sec.gov/Archives/edgar/data/1829802/000119312526444376/snse-20260930.htm

### July 11, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: with platinum-resistant ovarian cancer.
- First seen 2025-09-10, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-011080): "•New Drug Application - FDA reviewing NDA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with a July 11, 2026 PDUFA date" https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-25-048814): "•New Drug Application - FDA reviewing NDA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with a July 11, 2026 PDUFA date" https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm
- SEC Form 10-K (accession 0001628280-26-011091): "We have also submitted an NDA for relacorilant as a treatment, in combination with the chemotherapy medication nab-paclitaxel, for patients with platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026." https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-199706): "The FDA has assigned a PDUFA date of July 11, 2026 for the application." https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-199706): "FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026" https://www.sec.gov/Archives/edgar/data/1088856/000119312525199706/d947259dex991.htm

### late 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-11-03, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-444410): "We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027."" https://www.sec.gov/Archives/edgar/data/1829802/000119312526444410/d144290dex991.htm

### early 2028: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-10-15, last confirmed 2026-10-15.
- SEC Form 8-K (accession 0001628280-26-066006): "Pending results and further interactions with regulators, the Company plans to initiate the first of multiple Phase 3 trials of CR-001 in early 2028." https://www.sec.gov/Archives/edgar/data/1253689/000162828026066006/cbio-20261015.htm

## Same indication

- [Corcept](https://sec-api.dev/pdufa/corcept) (CORT)
- [Lifyorli™ (relacorilant)](https://sec-api.dev/pdufa/relacorilant) (CORT)
- [Rinatabart](https://sec-api.dev/pdufa/rinatabart) (GMAB)
- [Tovecimig](https://sec-api.dev/pdufa/tovecimig) (CMPX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/paclitaxel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAXOL® (paclitaxel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/paclitaxel

```bibtex
@misc{secapidev_pdufa_paclitaxel_20261116,
  title        = {TAXOL® (paclitaxel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/paclitaxel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_paclitaxel_20261116","title":"TAXOL® (paclitaxel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/paclitaxel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
